News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
China’s Simcere Pharmaceutical Group Sets IPO at 15.6 Million ADS
April 6, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, April 5 (Reuters) - China's Simcere Pharmaceutical Group set on Thursday its planned initial public offering at 15.6 million American depositary shares for an estimated $12.50 to $14.50 each.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Cancer
Roche finds another oncology gem in Asia with $1.5B B cell disease partnership
September 1, 2026
·
2 min read
·
Annalee Armstrong
Mergers & acquisitions
Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
August 31, 2026
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio
August 28, 2026
·
1 min read
·
Tristan Manalac
Deals
Biohaven could get up to $795M in epilepsy alliance with SK Bio
August 26, 2026
·
2 min read
·
Tristan Manalac
